donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

KNSA Kiniksa Pharmaceuticals

11.980
-0.200-1.64%
Close 08/17 16:00 ET
High
12.180
Open
12.100
Turnover
2.11M
Low
11.810
Pre Close
12.180
Volume
175.90K
Market Cap
832.26M
P/E(TTM)
Loss
52wk High
15.245
Shares
69.47M
P/E(Static)
Loss
52wk Low
7.360
Float Cap
322.47M
Bid/Ask %
-50.00%
Historical High
32.880
Shs Float
26.92M
Volume Ratio
0.55
Historical Low
5.010
Dividend TTM
--
Div Yield TTM
35
P/B
5.42
Dividend LFY
--
Div Yield LFY
292.15%
Turnover Ratio
0.65%
Amplitude
3.04%
Avg Price
11.982
Lot Size
1
Float Cap
322.47M
Bid/Ask %
-50.00%
Historical High
32.880
Shs Float
26.92M
Volume Ratio
0.55
Historical Low
5.010
Dividend TTM
--
P/B
5.42
Dividend LFY
--
Turnover Ratio
0.65%
Amplitude
3.04%
Avg Price
11.982
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.
CEO: Patel, Sanj K.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...